Renagel Related Published Studies
Well-designed clinical trials related to Renagel (Sevelamer)
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. [2008.06]
Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis. [2008.04]
Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. [2008.02]
Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients. [2008.01]
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study. [2008.01]
Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis. [2008]
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. [2007.11]
Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients. [2007.06]
Results of a randomized crossover study comparing once-daily and thrice-daily sevelamer dosing. [2006.09]
Sevelamer hydrochloride versus aluminum hydroxide: effect on serum phosphorus and lipids in CAPD patients. [2006.05]
A randomized crossover trial comparing sevelamer with calcium acetate in children with CKD. [2006.04]
Sevelamer worsens metabolic acidosis in hemodialysis patients. [2006.03]
Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. [2005.10]
Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients. [2005.08]
Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan. [2005.08]
Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. [2005.08]
Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. [2005.01]
Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients. [2004.06]
Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). [2004.05]
Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. [2004.01]
Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. [2003.12]
The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. [2003.09]
Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate. [2003.06]
Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. [2003.03]
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. [2002.07]
Sevelamer hydrochloride (Renagel), a phosphate-binding polymer, does not alter the pharmacokinetics of two commonly used antihypertensives in healthy volunteers. [2001.02]
Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. [2001.02]
Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. [2000.10]
A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. [1999.04]
A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. [1999.01]
Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. [1998.09]
Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. [1997.01]
Well-designed clinical trials possibly related to Renagel (Sevelamer)
K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. [2008.03]
Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. [2007.11]
Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. [2007.03]
Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. [2005.05]
Modeling the implications of changes in vascular calcification in patients on hemodialysis. [2005.04]
Long-term comparison of a calcium-free phosphate binder and calcium carbonate--phosphorus metabolism and cardiovascular calcification. [2004.08]
Effect of phosphate binders on supplemental iron absorption in healthy subjects. [2002.10]
Other research related to Renagel (Sevelamer)
Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. [2008.09.27]
Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. [2008.09]
Prevention and Management of Hyperphosphatemia with Sevelamer in Canada: Health and Economic Consequences. [2008.07.18]
Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. [2008.07]
Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. [2008.07]
Buffering effects of calcium carbonate as clarified by sevelamer hydrochloride monotherapy. [2008.06]
Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function. [2008.04.03]
Use of sevelamer hydrochloride as an oxalate binder. [2008.04]
[Treatment of secondary hyperparathyroidism in renal insufficiency: role of calcitriol, sevelamer and cinacalcet] [2008.03.05]
A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) Randomized Trial Using Claims Data. [2008.03]
Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients. [2008.03]
An economic evaluation of sevelamer in patients new to dialysis. [2008.02]
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. [2008.01]
Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis. [2008]
Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. [2008]
Short-Term Treatment with Sevelamer Increases Serum Fetuin-A Concentration and Improves Endothelial Dysfunction in Chronic Kidney Disease Stage 4 Patients. [2007.12.05]
A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. [2007.12]
Survival in end stage renal disease: calcium carbonate vs. sevelamer. [2007.12]
A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. [2007.12]
Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study. [2007.12]
Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels. [2007.12]
Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources. [2007.11]
The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. [2007.11]
Sevelamer hydrochloride in peritoneal dialysis patients: results of a multicenter cross-sectional study. [2007.11]
Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients. [2007.10]
Effect of sevelamer on aortic pulse wave velocity in patients on hemodialysis: a prospective observational study. [2007.10]
Economic evaluation of sevelamer in patients with end-stage renal disease. [2007.10]
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. [2007.08.29]
Sevelamer hydrochloride exacerbates metabolic acidosis in hemodialysis patients, depending on the dosage. [2007.04]
[Relationship between sevelamer HCl and vascular calcification] [2007.03]
Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. [2007.01]
Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. [2007]
Sevelamer and other anion-exchange resins in the prevention and treatment of hyperphosphataemia in chronic renal failure. [2007]
[Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients] [2007]
Pleiotropic effects of the non-calcium phosphate binder sevelamer. [2006.12]
Novel dosage forms and regimens for sevelamer-based phosphate binders. [2006.07]
Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders. [2006.04]
Sevelamer therapy for pediatric end-stage renal disease. [2006.03]
Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. [2006.03]
Long-term management of sevelamer hydrochloride-induced metabolic acidosis aggravation and hyperkalemia in hemodialysis patients. [2006]
A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients. [2006]
Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. [2005.11.01]
Gastric pH, sevelamer hydrochloride and omeprazole. [2005.10]
[Relationship between serum calcium level and PTH concentration proved with sevelamer hydrochloride] [2005.09]
[Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease] [2005.09]
[Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis] [2005.09]
[Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH] [2005.09]
[Treatment of adynamic bone disease with the complete replacement from calcium carbonate to sevelamer hydrochloride] [2005.09]
Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. [2005.09]
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. [2005.08]
Impact of sevelamer hydrochloride and the K/DOQI guidelines. [2005.08]
Role of sevelamer hydrochloride in the coronary artery calcification score. [2005.08]
Introduction to sevelamer hydrochloride and its clinical effects. [2005.08]
Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy. [2005.08]
Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. [2005.05]
Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines. [2005.02]
The influence of dialysate calcium on the therapeutic effects of sevelamer hydrochloride in hemodialysis patients with secondary hyperparathyroidism under treatment of intravenous vitamin d metabolites. [2005.02]
Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. [2005.02]
[Sevelamer:hydrochloride.] [2005.01]
Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients. [2005]
Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by sevelamer hydrochloride. [2005]
Peritoneal dialysis patients using sevelamer do not present the acidosis problems that hemodialysis patients do. [2005]
|
